TickerGuard
Buy Day today: Good (62) Broad market participation · no major macro event
ATYR

aTyr Pharma, Inc.

Healthcare · Biotechnology

0.3765$ -2.0% vs. previous close Closing price · As of: Sep 17, 2026

Ownership

Ownership Structure

Who owns aTyr Pharma, Inc. (ATYR)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 99.6% of the shares are freely tradable; institutional investors hold 48.6%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 48.6%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 2.5%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 99.6%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 10.9%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 98Mio.

Largest Shareholders

Institutions

Institutions ATYR
Name Stake (%) Shares Change (%) Date
FMR Inc 14.99 14,706,843 +0.1 03/31/2026
Federated Hermes Inc 8.68 8,509,678 -19.0 06/30/2026
BlackRock Inc 6.57 6,443,904 -1.6 03/31/2026
UBS Group AG 3.94 3,867,213 +137.9 03/31/2026
Vanguard Capital Management, LLC 3.89 3,812,132 +0.0 03/31/2026
GSA Capital Partners LLP 3.52 3,454,863 +105.1 06/30/2026

Funds

Funds ATYR
Name Stake (%) Shares Change (%) Date
Federated Hermes Kaufmann Growth 4.45 4,367,290 -21.8 06/30/2026
Federated Hermes Kaufmann R 4.45 4,367,290 -21.8 06/30/2026
Federated Hermes Kaufmann Small Cap A 4.14 4,061,288 -15.5 06/30/2026
Federated Hermes Kaufmann Small Cap Grow 4.14 4,061,288 -15.5 06/30/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?